News
![Danish pharma company Novo Nordisk](https://pharmaphorum.com/wp-content/uploads/2018/04/Novo-Nordisk-HQ-flag.jpg)
Novo Nordisk builds cardio claim case for oral semaglutide
Novo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has advanced again with new data showing it is safe for the heart.